Jove
Visualize
Contact Us

Related Experiment Videos

Antiparasitic agents.

J E Rosenblatt1

  • 1Division of Clinical Microbiology, Mayo Clinic Rochester, Minnesota 55905, USA.

Mayo Clinic Proceedings
|November 24, 1999
PubMed
Summary
This summary is machine-generated.

Newer medications offer improved treatment and prevention for parasitic infections like malaria and babesiosis. Research highlights effective options for drug-resistant malaria and infections in immunocompromised patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Donor-transmitted toxoplasmosis in liver transplant recipients: a case report and literature review.

Transplant infectious disease : an official journal of the Transplantation Society·2007
Same author

Real-time PCR in clinical microbiology: applications for routine laboratory testing.

Clinical microbiology reviews·2006
Same author

Comparison of the Roche LightCycler vanA/vanB detection assay and culture for detection of vancomycin-resistant enterococci from perianal swabs.

Journal of clinical microbiology·2004
Same author

Real-time PCR method for detection of Encephalitozoon intestinalis from stool specimens.

Journal of clinical microbiology·2002
Same author

Multilaboratory comparison of growth characteristics for anaerobes, using 5 different agar media.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2002
Same author

Multilaboratory comparison of anaerobe susceptibility results using 3 different agar media.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2002
Same journal

Advancing Pulmonary Fibrosis Care: Integrating Genomic Insights Into Clinical Practice.

Mayo Clinic proceedings·2026
Same journal

RAAS Inhibition in the ICU: Stop, Continue, or Restart?

Mayo Clinic proceedings·2026
Same journal

Chronic Kidney Disease-In the Limelight, July 2026.

Mayo Clinic proceedings·2026
Same journal

In Reply: Long-Term Cardiovascular Burden After Carotid Endarterectomy: Moving Beyond Conventional Risk Profiling.

Mayo Clinic proceedings·2026
Same journal

Long-Term Cardiovascular Burden After Carotid Endarterectomy: Moving Beyond Conventional Risk Profiling.

Mayo Clinic proceedings·2026
Same journal

Real-World Comparative Effectiveness of Tirzepatide and Semaglutide for Obesity: A Multicentered Study.

Mayo Clinic proceedings·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Tropical Medicine
  • Infectious Diseases
  • Pharmacology

Background:

  • Parasitic infections pose significant global health challenges.
  • Emerging drug resistance in pathogens like Plasmodium falciparum necessitates novel therapeutic strategies.
  • Advancements in chemotherapy and prophylaxis are crucial for managing a spectrum of parasitic diseases.

Purpose of the Study:

  • To review recent developments in the chemotherapy and prophylaxis of parasitic infections.
  • To evaluate the efficacy and safety of emerging anti-parasitic agents.
  • To highlight new treatment options for drug-resistant malaria and opportunistic infections.

Main Methods:

  • Review of recent clinical studies and pharmacological data.
  • Analysis of treatment outcomes for various parasitic infections.

Related Experiment Videos

  • Assessment of side effect profiles and safety data for new agents.

    • Main Results:

    • Mefloquine is effective for chloroquine-resistant malaria, with low-dose regimens showing comparable side effects to chloroquine.
    • New agents like Malarone (atovaquone/proguanil), artemisinin derivatives, halofantrine, azithromycin, albendazole, ivermectin, and liposomal amphotericin B show promise.
    • Artemisinin derivatives are effective against multidrug-resistant Plasmodium falciparum.
    • Azithromycin combinations show efficacy in babesiosis, cryptosporidiosis, and toxoplasmosis.
    • Albendazole is a key treatment for microsporidiosis, echinococcosis, and neurocysticercosis.
    • Liposomal amphotericin B is approved for visceral leishmaniasis.

    Conclusions:

    • Several new agents offer improved or alternative treatment options for parasitic infections.
    • Careful consideration of side effects and specific indications is necessary for agents like mefloquine and halofantrine.
    • Ongoing research is vital to combat drug resistance and address unmet needs in parasitic disease management.